{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:15:11Z","timestamp":1760552111355,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Juvenile myasthenia gravis (MG) is a rare autoimmune neuromuscular disease, often treated with anticholinesterases, corticosteroids, and immunosuppressants. However, optimal treatment durations remain unclear. This study investigated the clinical characteristics and treatment of juvenile MG, including medication duration. The administration period for all drugs, immunosuppressants, and prednisolone at doses greater than 0.35 mg\/kg daily was extracted retrospectively from medical records. Nineteen participants (8 boys, 11 girls) aged 8 months to 14 years (median, 2.5 years) at onset were identified. Fourteen patients (73.7%) had ocular MG and five (26.3%) had generalized MG. Drug treatment was conducted in 18 cases; however, 7 patients did not complete the treatment. Among the patients who completed drug treatment, the duration of treatment ranged from 11 to 100 months (median, 47 months). In the six patients treated with continuous administration of prednisolone or immunosuppressants, the treatment duration ranged from 33 to 99 months (median, 56 months). No severe adverse effects requiring hospitalization were reported. The patients treated with prednisolone or immunosuppressants required at least 33 months of treatment. These results will help develop protocols for juvenile MG treatment.<\/jats:p>","DOI":"10.3390\/children11050572","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T03:21:04Z","timestamp":1715311264000},"page":"572","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Characteristics and Treatment of Juvenile Myasthenia Gravis\u2014A Single-Center Experience"],"prefix":"10.3390","volume":"11","author":[{"given":"Mikiko","family":"Maeda","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Hyogo Medical University School of Medicine, 1-1, Mukogawa, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-9193","authenticated-orcid":false,"given":"Hideki","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hyogo Medical University School of Medicine, 1-1, Mukogawa, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachi","family":"Tokunaga","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hyogo Medical University School of Medicine, 1-1, Mukogawa, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hyogo Medical University School of Medicine, 1-1, Mukogawa, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hyogo Medical University School of Medicine, 1-1, Mukogawa, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6468-7185","authenticated-orcid":false,"given":"Yasuhiro","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hyogo Medical University School of Medicine, 1-1, Mukogawa, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"ref_1","unstructured":"Swaiman, K.F., Ashwal, S., Ferriero, S.M., Schor, N.F., Finkel, R.S., Gropman, A.L., Pearl, P.L., and Shevell, M. (2017). Swaiman\u2019s Pediatric Neurology: Principles and Practice, Elsevier. [6th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.spen.2017.04.003","article-title":"Pediatric myasthenia gravis","volume":"24","author":"Peragallo","year":"2017","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_3","first-page":"S152","article-title":"Childhood myasthenia gravis: Clinical features and outcomes","volume":"94","author":"Panichai","year":"2011","journal-title":"J. Med. Assoc. Thai"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jocn.2023.08.022","article-title":"Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis","volume":"116","author":"Zhang","year":"2023","journal-title":"J. Clin. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"996213","DOI":"10.3389\/fped.2022.996213","article-title":"Clinical characteristics and outcome predictors of a Chinese childhood-onset myasthenia gravis cohort","volume":"10","author":"Yang","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pediatrneurol.2018.06.007","article-title":"Juvenile ocular myasthenia gravis: Presentation and outcome of a large cohort","volume":"87","author":"Vanikieti","year":"2018","journal-title":"Pediatr. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.nmd.2021.11.014","article-title":"Spontaneous remission in juvenile myasthenia gravis: A cohort of 13 cases and review of the literature","volume":"32","author":"Arroyo","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2021.01.009","article-title":"Pediatric autoimmune ocular myasthenia gravis: Evaluation of presentation and treatment outcomes in a large cohort","volume":"118","author":"Fisher","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","article-title":"The natural course of myasthenia gravis: A long term follow up study","volume":"52","author":"Oosterhuis","year":"1989","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaad.2016.02.1241","article-title":"Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients","volume":"76","author":"Caplan","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00415-015-7638-2","article-title":"Long-term outcome of 424 childhood-onset myasthenia gravis patients","volume":"262","author":"Gui","year":"2015","journal-title":"J. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: Recommendations for clinical research standards. Task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: A double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurol. Scand."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1212\/WNL.37.12.1854","article-title":"Myasthenia gravis: Population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians","volume":"37","author":"Chiu","year":"1987","journal-title":"Neurology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s10072-013-1329-5","article-title":"A cohort study on myasthenia gravis patients in China","volume":"34","author":"Wang","year":"2013","journal-title":"Neurol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/mus.21195","article-title":"Juvenile myasthenia gravis","volume":"39","author":"Chiang","year":"2009","journal-title":"Muscle Nerve"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11940-019-0593-y","article-title":"Pediatric ocular myasthenia gravis","volume":"21","author":"Fisher","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data","volume":"65","author":"Jacobs","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"31S","DOI":"10.1016\/S0002-9343(97)90006-1","article-title":"Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence","volume":"103","author":"Saag","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0022-3476(94)70219-5","article-title":"Prednisone dose limitation of growth hormone treatment of steroid-induced growth failure","volume":"125","author":"Rivkees","year":"1994","journal-title":"J. Pediatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0889-8529(05)70348-0","article-title":"Growth suppression by glucocorticoid therapy","volume":"25","author":"Allen","year":"1996","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3892\/etm.2015.2256","article-title":"Clinical characteristics and therapeutic evaluation of childhood myasthenia gravis","volume":"9","author":"Yang","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e02203","DOI":"10.1002\/brb3.2203","article-title":"No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients","volume":"11","author":"Wang","year":"2021","journal-title":"Brain Behav."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/5\/572\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:43:00Z","timestamp":1760107380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/5\/572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["children11050572"],"URL":"https:\/\/doi.org\/10.3390\/children11050572","relation":{},"ISSN":["2227-9067"],"issn-type":[{"type":"electronic","value":"2227-9067"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}